Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neprilysin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Neprilysin. Displaying page 1 of 1.
    EudraCT Number: 2017-002020-25 Sponsor Protocol Number: 052017 Start Date*: 2018-08-31
    Sponsor Name:Odense University Hospital
    Full Title: ANGIOTENSIN–NEPRILYSIN INHIBITION IN DIASTOLIC DYSFUNCTION AFTER AMI
    Medical condition: Diastolic dysfunction after acute myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000394-36 Sponsor Protocol Number: M17-05-LCZ-ARNI Start Date*: 2017-12-20
    Sponsor Name:Hannover Medical School
    Full Title: Influences of angiotensin-neprilysin inhibition with Sacubitril/Valsartan (ENTRESTO®) on centrally generated sympathetic activity in heart failure patients
    Medical condition: Chronic heart failure with reduced left ventricular ejection fraction (NYHA II-III)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000185-42 Sponsor Protocol Number: VX19-147-101 Start Date*: 2020-06-01
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis.
    Medical condition: APOL1-mediated Focal segmental glomerulosclerosis (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002168-17 Sponsor Protocol Number: BAY94-8862/16275 Start Date*: 2015-12-09
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to evaluate the efficacy and safety of finerenone compared to eplerenone on morbidity and mortality in...
    Medical condition: Subjects with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    20.0 100000004849 10066498 Cardiac failure chronic aggravated LLT
    21.0 100000004857 10076408 Chronic kidney disease stage 1 LLT
    21.0 100000004857 10076409 Chronic kidney disease stage 2 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) LT (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004882-15 Sponsor Protocol Number: EntREG-SILICOFCM Start Date*: 2019-05-21
    Sponsor Name:University Hospital Regensburg
    Full Title: Effect of angiotensin receptor neprilysin inhibitor sacubitril/valsartan on cardiopulmonary exercise tolerance in patients with hypertrophic cardiomyopathy – a randomized controlled clinical Phase ...
    Medical condition: hypertrophic cardiomyopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003839-38 Sponsor Protocol Number: BAY1067197/15128 Start Date*: 2017-03-09
    Sponsor Name:Bayer AG
    Full Title: A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral parti...
    Medical condition: chronic heart failure with reduced ejection fraction (LVEF equal or below 35%)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) BE (Completed) GR (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002299-28 Sponsor Protocol Number: 20110203 Start Date*: 2017-01-17
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Redu...
    Medical condition: Chronic Heart Failure With Reduced Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) SE (Completed) CZ (Completed) ES (Completed) HU (Completed) NL (Completed) GB (Completed) PT (Completed) PL (Completed) AT (Completed) SK (Completed) BG (Completed) LT (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003555-35 Sponsor Protocol Number: PAT-DEU-402 Start Date*: 2017-11-17
    Sponsor Name:Fresenius Medical Care Nephrologica Deutschland GmbH
    Full Title: A Multicentre, Randomised, Open-label, Parallel-Group Pilot Study to Evaluate the Efficacy of Patiromer in Optimising Mineralocorticoid Receptor Antagonist Therapy in Heart Failure Subjects with Hy...
    Medical condition: Heart Failure with reduced ejection fraction (HFrEF) subjects with hyperkalaemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 10027433 - Metabolism and nutrition disorders 10020646 Hyperkalaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-005093-19 Sponsor Protocol Number: AT251-G-17-005 Start Date*: 2019-01-08
    Sponsor Name:Akros Pharma Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JTT-251 Administered for 24 Weeks to Participants with Heart Failure with Reduced E...
    Medical condition: Heart Failure with Reduced Ejection Fraction (HFrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Completed) DK (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001124-66 Sponsor Protocol Number: 15774603 Start Date*: 2016-07-08
    Sponsor Name:University Hospital Toulouse
    Full Title: Evaluation of the effect of double inhibition of angiotensin II AT1 receptor and neprilysin activity on sympatic nervous system activity in patient with heart failure (B2AN-SNS)
    Medical condition: Heart failure
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002429-39 Sponsor Protocol Number: Leodor2017 Start Date*: 2017-10-27
    Sponsor Name:Medical University Innsbruck
    Full Title: REPETITIVE LEVOSIMENDAN INFUSIONS FOR PATIENTS WITH ADVANCED CHRONIC HEART FAILURE
    Medical condition: Advanced chronic heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) HU (Completed) SI (Completed) FI (Completed) DK (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002239-11 Sponsor Protocol Number: MYK-491-003 Start Date*: 2019-04-18
    Sponsor Name:MyoKardia Inc.
    Full Title: Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses...
    Medical condition: Heart Failure with Reduced Ejection Fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) NL (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002946-19 Sponsor Protocol Number: 1245-0204 Start Date*: 2020-01-15
    Sponsor Name:Boehringer Ingelheim
    Full Title: A multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, ini...
    Medical condition: Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) BE (Completed) DE (Completed) DK (Completed) ES (Completed) HU (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003626-24 Sponsor Protocol Number: MYK-491-006 Start Date*: 2020-04-06
    Sponsor Name:MyoKardia Inc.
    Full Title: An Open-Label, Exploratory Study of the Safety and Preliminary Efficacy of Danicamtiv in Stable Ambulatory Participants with Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants or Oth...
    Medical condition: Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-003312-27 Sponsor Protocol Number: D9480C00018 Start Date*: 2021-03-02
    Sponsor Name:AstraZeneca AB
    Full Title: Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate (SZC) for the Management of Hyperkalaemia in Patients with Symptomatic Heart Failur...
    Medical condition: Hyperkalemia in Patients with Symptomatic Heart Failure.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10020646 Hyperkalaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003460-13 Sponsor Protocol Number: GN16CA007 Start Date*: 2018-02-13
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: The effects of sacubitril/valsartan compared to valsartan on left ventricular remodelling in patients with asymptomatic left ventricular systolic dysfunction after myocardial infarction: a randomi...
    Medical condition: Asymptomatic (New York Heart Association ≤2) left ventricular systolic dysfunction (defined as ejection fraction ≤40% measured by Simpson's biplane using transthoracic echocardiography) at least 3...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019279 Heart failure LLT
    20.1 10007541 - Cardiac disorders 10064079 Heart failure NYHA class I LLT
    20.0 10007541 - Cardiac disorders 10069501 Left ventricular systolic dysfunction LLT
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-004727-37 Sponsor Protocol Number: CAAA603A12101 Start Date*: 2019-02-18
    Sponsor Name:Advanced Accelerator Applications International SA
    Full Title: A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with...
    Medical condition: Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001467-36 Sponsor Protocol Number: FER-CARS-06 Start Date*: 2017-02-02
    Sponsor Name:Vifor (International) Inc.
    Full Title: A Randomised, Double-blind Placebo Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart F...
    Medical condition: Acute heart failure with iron deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    20.0 100000011689 10000803 Acute heart failure LLT
    20.0 10027433 - Metabolism and nutrition disorders 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) PL (Completed) HR (Completed) SE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:03:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA